SAN DIEGO, Calif. – September 30, 2019 – Results from a study sponsored by Stemedica Cell Technologies, Inc., a global biotechnology company that uses allogeneic stem cells for ischemic conditions, form the basis for a peer-reviewed paper published in Stroke entitled “Phase I/II Study of Safety and Preliminary Efficacy of Intravenous Allogeneic Mesenchymal Stem Cells in Chronic Stroke.” Co-authors include Michael L. Levy, MD, PhD, John R. Crawford, MD, Nabil Dib, MD, Lev Verkh, PhD, Nikolai Tankovich, MD, PhD and Steven C. Cramer, MD. [Read more…]
PLEXOVAL Exosome Wound Healing Human Study Starts
-
A world-first study using cell free exosome product manufactured using Exopharm’s LEAP Technology
-
Study sites at the Royal Melbourne Hospital and Australian Red Cross Blood Service
-
Results by mid 2020
26 August 2019, Melbourne, Australia: Regenerative medicine company Exopharm Limited (ASX:EX1) announces the start of the PLEXOVAL Phase 1 study, the first human clinical trial using exosomes for wound healing. [Read more…]
denovoMATRIX Introduces Ready-to-use, Chemically Defined Coated Cell Cultureware for Serum-free hMSC Expansion
August 22, 2019, Dresden, Germany — Due to their high accessibility and extensive beneficial properties, human Mesenchymal Stem Cells (hMSC) offer exciting promises in a plethora of applications in regenerative medicine, particularly in cell-based therapies. The major challenge of hMSC-based therapy is the large-scale expansion of cells in order to achieve the cell numbers necessary for therapeutic treatment. [Read more…]
Nucleus Biologics acquires Primorigen Biosciences, gains proprietary, high yield, recombinant protein platform
SAN DIEGO, Aug. 6, 2019 — Nucleus Biologics, a leader in precision cell culture, is pleased to announce the acquisition of Primorigen Biosciences, Inc. The addition of Primorigen’s Vitronectin XF™ and platform recombinant protein production technology will play a huge role in Nucleus’ strategy of offering traceable, reproducible and xeno-free (XF) cell culture ecosystems for the cell and gene therapy space. [Read more…]
GenCure announces breakthrough first run of 80-liter bioreactor
Biomanufacturing CDMO among first to harvest adult stem cells at large scale
SAN ANTONIO, Texas – In a breakthrough for the regenerative medicine industry, GenCure announced today that its biomanufacturing services team has successfully completed production runs expanding and harvesting human mesenchymal stem cells (hMSCs) in an 80-liter bioreactor. GenCure, a subsidiary of BioBridge Global (BBG), announced a major expansion of its biomanufacturing facilities in February of this year. [Read more…]
- « Previous Page
- 1
- …
- 72
- 73
- 74
- 75
- 76
- …
- 96
- Next Page »